Novartis has been experiencing an upward trend with shares gaining 12% over the three months. This has likely resulted from a combination of factors including successful
phase III trials of Cosentyx in Polymyalgia Rheumatica,
Q3 earnings estimates, and the perception of the stock by growth investors.
Regulus Therapeutics acquisition completion and the FDA's approval for a pill treatment for skin flare-ups also contributed. Despite favorable factors, there were some concerns such as Goldman Sachs's recommendation to sell due to the stock being overvalued. This advice was based upon growth concerns. In response to the pharma tariff announcement by Trump,
Novartis maintained its U.S. plans. The company is doing well in its Q2 performance, initiating a $10 billion stock buyback. Notably,
Novartis has agreed to a $1.4 billion deal to acquire Tourmaline Bio. Despite positive growth, there are warnings about potential downside due to generics and recent downgrades to sell from some financial institutions.
Novartis Stocks News Analytics from Sat, 22 Feb 2025 08:00:00 GMT to Sat, 25 Oct 2025 23:23:12 GMT -
Rating 6
- Innovation 4
- Information 8
- Rumor -5
